Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 5

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 5
---
, posters and presentations, including a presentation at the European Society for Medical Oncology (ESMO) 2024 Congress on new data from the STAMPEDE trial, a multi-center, randomized, phase 3 clinical trial showing that the test was prognostic for clinical outcomes and predicted benefit from docetaxel in patients with metastatic prostate cancer.

• Received Medicare coverage for Afirma testing of patients with thyroid nodules classified as “Bethesda V,” giving more patients access to the test annually.

Governance and Board Highlights

#### Board Composition

#### Gender

#### Age

#### Tenure

#### Independence

#### Veracyte2025 Proxy Statement5

#### Proxy Statement Summary

#### Governance and Board Practices
We are committed to good corporate governance, which strengthens the accountability of our Board of Directors and promotes the long-term interests of our stockholders. The list below highlights our independent board and leadership and other corporate governance practices, as discussed further in this Proxy Statement. • Majority of directors are independent (eight out of nine current directors). • Board leadership structure with an independent Chair of the Board of Directors. • All committees of our Board of Directors, including our Regulatory and Compliance Committee, are composed only of independent directors. • Following approval by our stockholders at the 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”), we filed a Restated Certificate of Incorporation (the “Restated Certificate”) to implement a declassification of the Board of Directors over a three-year period and provide for the annual election of directors for one-year terms, commencing upon the expiration of the directors’ then-current terms. Beginning with our 2026 Annual Meeting of Stockholders, all director nominees will stand for election for only one-year terms, such terms expiring at the next Annual Meeting of Stockholders. • Our Nominating and Corporate Governance Committee oversees our programs relating to corporate responsibility and sustainability, including Environmental, Social, and Corporate Governance (“ESG”), in collaboration with our Audit Committee, Compensation Committee, and Regulatory and Compliance Committee on certain ESG matters, as appropriate and as described in each respective committee charter. • We provide annual reporting on corporate responsibility and sustainability initiatives for those investors who are focused on these topics. • Our Board of Directors is focused on enhancing the composition of the Board. Currently, two out of our nine members of the Board of Directors are women, and two out of nine members of the Board of Directors are from underrepresented groups. • We employ comprehensive enterprise risk management practices, including oversight